Penwood is an essay newsletter by a commercial leader who advises biopharma and MedTech companies on launch strategy and AI adoption. Each issue argues a specific point, such as why launches miss forecasts, why commercial teams stall on AI, or why connected-device data decisions belong before regulatory clearance, backed by industry studies and the author's experience at Novartis and Sanofi.
Website: https://www.penwood.com/
Short, sourced news briefs on the peptide supply chain, covering product launches, manufacturing facilities and raw-material capacity. Each item notes what the source did not disclose, such as capacity, pricing or orders.
BioCompounding publishes long-form equity research on medtech and biopharma companies, including earnings reviews and company deep dives. It also explains industry structure, such as how generics and biosimilars differ as businesses.
A daily-style biopharma newsletter offering commentary on therapeutics, regulatory oversight and clinical trials, organised around weekday themes. Readers get a short, opinionated take on industry developments such as biosimilar choices, regulator priorities and upcoming conference data.
A weekly newsletter tracking AI and computational drug discovery, covering deals, startups, funding rounds and research papers in biopharma. Each issue pairs a main analytical essay with a roundup of recent industry news.
One short email a week with hand-picked newsletters from the index. Free, no spam, unsubscribe anytime.
